ATTO Stock Forecast & Price Target

Attovia Therapeutics is viewed positively because its ATTOBODY platform may create differentiated mono- and multispecific biologics against validated immune targets, reducing scientific risk while addressing large markets in chronic pruritus, atopic dermatitis, and IBD. ATTO-1310 already showed competitive week 4 efficacy in CPUO and AD, and its IL-31 ligand design plus YTE half-life extension could support quarterly maintenance dosing and meaningful uptake in a market modeled at more than $2.7B worldwide peak sales. ATTO-2306 and ATTO-1091 add upside through bispecific and trispecific approaches that combine well-validated pathways, with projected U.S. sales for ATTO-1310 alone reaching $1.875 billion and key catalysts spanning 4Q26/1Q27, 1H27, 2H27, and 2027.

Attovia Therapeutics is a clinical-stage, pre-revenue biotech whose valuation depends almost entirely on ATTO-1310, ATTO-2306, and ATTO-1091 proving clear safety and efficacy advantages in crowded immune-dermatology and IBD markets. The excerpts highlight that the company’s core biologic strategy has not fully translated in humans, with ATTO-1310 potentially offering fewer advantages over Nemluvio and related approaches, while smaller-size/penetration claims have already proven inferior to traditional antibodies like Bimzelx in hidradenitis suppurativa. With no marketed products, ongoing R&D funding needs, and risks of trial failure, regulatory delay, weak commercialization, and dilution from future capital raises, the downside case is fundamentally driven by limited evidence of differentiation and an elevated financing burden.